Tiziana Life Sciences Ltd. Common Shares (TLSA)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, consistent earnings, and a conservative balance sheet. Tiziana is the opposite profile: a ten-employee clinical-stage biotech with a lead anti-CD3 antibody, Foralumab TZLS-401, in Phase II for non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis. There is no revenue growth or profit growth figure supplied, and FairStock's Lynch category is none because only 0 years of filed results exist where three are needed. The financial health is poor by the numbers. At the 2026-10-13 close of $1.09, FairStock shows a negative P/E of -6.81, P/B of 17.13, ROE of -924.32%, ROCE of -115.96%, debt-to-equity of 8.77, Piotroski F-Score of 0/9, and Altman Z-Score of -11.97. A P/B above 17 is not an asset bargain; it is a high price relative to book value. The Altman score and Piotroski score signal severe financial weakness. The market cap is $155.9M, and the FairStock Score is only 25/100. The 52-week range is $0.76-$2.15, so the price is below the midpoint but still not cheap on current fundamentals. The investment case rests almost entirely on clinical trial outcomes and potential partnerships, not on present earnings or a moat. I see no margin of safety in the reported numbers; this is a speculative pipeline bet, not a Graham-style value stock.

In plain English: Tiziana Life Sciences is a small healthcare company working on experimental medicines for brain and nerve diseases. It has only 10 employees, is not currently profitable, and the financial numbers shown are weak. At $1.09 on 2026-10-13, the price looks expensive compared with those numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer